|
| Included studies | Design | Disease | Location | No. of eyes 27G/25G | Age (year) mean ± SD 27G/25G | Followup (months) | Complications (eyes) 27G/25G |
|
| Reibaldi et al. [21] | Prospective randomized comparative study | ERM | Italy | 40/39 | 66 ± 6/64 ± 6
= 0.14 | 12 | IRB: 0/3
VH: 2/3
Hypotony: 1/2
ERM recurrence: 3/2 |
| Mitsuiet al. [15] | Prospective nonrandomized comparative study | ERM | Japan | 32/36 | 68.9 ± 5.3/65.4 ± 11.4
= 0.33 | 6 | Hypotony: 3/4 |
| Takashina et al. [17] | Retrospective randomized comparative study | ERM | Japan | 59/88 | 72.9 ± 6.3/71.3 ± 7.9
: NA | 1 | NA |
| Rizzo et al. [9] | Prospective nonrandomized comparative study | RRD | Italy | 20/20 | 64.7 ± 9.7/62.4 ± 9.8
: NA | 6 | IRB: 2/1
Choroidal detachment: 1/0
RD: 2/3
Intraocular hypertension: 1/2 |
| Naruse et al. [29] | Retrospective nonrandomized clinical trial | ERM | Japan | 100/100 | 67.6 ± 9.6/69.4 ± 8.9
= 0.25 | 6 | RD: 0/1
VH: 1/1
Hypotony: 2/6
Intraocular hypertension: 4/10 |
| Romanoet al. [23] | Prospective randomized comparative study | RRD | Italy | 15/15 | 58 ± 8/59 ± 11
= 0.82 | 6 | RD: 1/1
VH: 1/0
Intraocular hypertension: 0/2 |
| Liet al. [30] | Retrospective nonrandomized clinical trial. | RRD | China | 34/58 | 58.5 ± 13.3/54.1 ± 12.5
= 0.1 | 6 | RD: 3/3
IRB: 1/2
Hypotony: 0/1
Intraocular hypertession: 0/1 |
| Lubinski et al [24] | Prospective randomized comparative study | ERM | Poland | 30/30 | 65.40 ± 4.29/67.50 ± 4.18
= 0.052 | 6 | RD: 1/1
Macular hole: 1/0
Hypotony: 3/7 |
| Otsuka et al. [25] | Retrospective nonrandomized clinical trial | RRD | Japan | 30/32 | 59 ± 13/55 ± 9
= 0.15 | 6 | RD: 1/2 |
| Sborgia et al. [31] | Prospective randomized comparative study | RRD | Italy | 42/46 | 59.9 ± 9.2/61.7 ± 8.7
= 0.35 | 12 | RD: 4/2
Choroidal detachment: 1/0
ERM: 5/2
CME: 2/1 |
| Veritti et al. [26] | Prospective randomized comparative study | RRD | Italy | 37/37 | 63.9 ± 13.5/63.1 ± 12.5
= 0.8 | 6 | RD: 4/3
Hypotony: 0/2
Intraocular hypertension: 4/5
Wound suture: 3/11 |
|
